ID
13431
Description
Antibiotic-associated diarrhoea (AAD) is a frequent condition in hospitalised patients receiving antibiotic treatment. The same is true for Clostridium difficile-associated diarrhoea (CDAD) with even more grave consequences of increased morbidity and mortality. The development and evaluation of preventive strategies is one key public health challenge. In the absence of clinically evaluated alternatives, probiotics have been suggested to be beneficial for the prevention of AAD and CDAD. However, data have so far been inconclusive and recently published meta-analyses strongly recommended large state-of-the-art clinical trials on probiotic substances for the prevention of AAD and CDAD. Since the efficacy, side-effects and modes of action of different probiotic bacteria and yeast are strain specific, benefits and risks cannot be generalised. The non-pathogenic yeast Saccharomyces cerevisiae var. boulardii (Sac. boulardii) is considered the most promising probiotic substance for the prevention of AAD and CDAD. We carry out a randomised, placebo controlled, double blind multicentre clinical trial to evaluate Sac. boulardii for the indication of prevention of AAD and CDAD in 1520 adult, hospitalised patients. Please note: 1) At first hospitalization please enter the antibiotic initially used in the first line! 2) Please enter the medication in chronological order! 3) Obligatory documentation starts with the date the (re-) hospitalization begins! If there is preexisting medication the starting date is determined as follows: a) First hospitalization = Date of first dose of antibiotic! b) Rehospitalization = Date of Rehospitalization! 4) Documentation of the last dose of any of the medication subject for documentation is only necessary until the regular end of the study.
Mots-clés
Versions (2)
- 08/02/2016 08/02/2016 -
- 11/02/2016 11/02/2016 -
Téléchargé le
11 février 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
SacBo PZ: Case Report Form Hospitalization Medication subject to documentation DRKS00000084 NCT01143272
SacBo PZ: Case Report Form Hospitalization Medication subject to documentation NCT01143272
Description
Further medication subject to documentation
Description
Number of medication
Type de données
text
Description
Medication
Type de données
integer
Alias
- UMLS CUI [1]
- C0013227
Description
First dose
Type de données
date
Alias
- UMLS CUI [1,1]
- C3174092
- UMLS CUI [1,2]
- C0205435
- UMLS CUI [1,3]
- C0011008
Description
Last dose
Type de données
date
Alias
- UMLS CUI [1]
- C1762893
Similar models
SacBo PZ: Case Report Form Hospitalization Medication subject to documentation NCT01143272
C0235952 (UMLS CUI [2])
C0205435 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,2])
C0205435 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
Aucun commentaire